Literature DB >> 8105839

HER-2 and INT-2 amplification estimated by quantitative PCR in paraffin-embedded ovarian cancer tissue samples.

C Hruza1, K Dobianer, A Beck, K Czerwenka, H Hanak, M Klein, S Leodolter, M Medl, S Müllauer-Ertl, J Preiser.   

Abstract

Competitive polymerase chain reaction (PCR) systems were developed for rapid and quantitative estimation of HER-2 (c-erbB-2) and INT-2 oncogene amplification in paraffin-embedded ovarian cancer tissue samples. The beta-globin gene was used as reference and DNA from paraffin-embedded placenta tissue as single copy control. Reliability of the PCR method could be demonstrated by comparing dot blot data with PCR data of identical tumour samples. The PCR method was used to determine HER-2 and INT-2 copy numbers in 196 ovarian cancer samples. HER-2 and INT-2 were found to be amplified in 40 and 19%, respectively. In 8% HER-2 copy numbers were greater than five, but no high INT-2 copies were noted. Kaplan-Meier estimates did not reveal significant association with overall survival. Indirect correlation between HER-2 and INT-2 amplification was observed. The present PCR system is a valuable method for prospective and retrospective studies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105839     DOI: 10.1016/0959-8049(93)90301-u

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.

Authors:  Claire Cole; Sin Lau; Alison Backen; Andrew Clamp; Graham Rushton; Caroline Dive; Cassandra Hodgkinson; Rhona McVey; Henry Kitchener; Gordon C Jayson
Journal:  Cancer Biol Ther       Date:  2010-09-04       Impact factor: 4.742

Review 2.  Quantitative PCR. A survey of the present technology.

Authors:  U Reischl; B Kochanowski
Journal:  Mol Biotechnol       Date:  1995-02       Impact factor: 2.695

3.  The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.

Authors:  Bozena Konopka; Aneta Janiec-Jankowska; Zygmunt Paszko; Marian Goluda
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-09       Impact factor: 4.553

4.  Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas.

Authors:  J Tapper; R Bützow; T Wahlström; M Seppälä; S Knuutila
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Critical determination of the frequency of c-erbB-2 amplification in breast cancer.

Authors:  A L Hubbard; C P Doris; A M Thompson; U Chetty; T J Anderson
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.